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Biosystems (INBB), Rome, ItalyTo date, the study of the sympathetic regulation of renal
function has been restricted to the important contribution
of b1- and b2-adrenergic receptors (ARs). Here we
investigate the expression and the possible physiologic
role of b3-adrenergic receptor (b3-AR) in mouse kidney. The
b3-AR is expressed in most of the nephron segments that
also express the type 2 vasopressin receptor (AVPR2),
including the thick ascending limb and the cortical and
outer medullary collecting duct. Ex vivo experiments in
mouse kidney tubules showed that b3-AR stimulation with
the selective agonist BRL37344 increased intracellular
cAMP levels and promoted 2 key processes in the urine
concentrating mechanism. These are accumulation of the
water channel aquaporin 2 at the apical plasma membrane
in the collecting duct and activation of the Na-K-2Cl
symporter in the thick ascending limb. Both effects were
prevented by the b3-AR antagonist L748,337 or by the
protein kinase A inhibitor H89. Interestingly, genetic
inactivation of b3-AR in mice was associated with
signiﬁcantly increased urine excretion of water, sodium,
potassium, and chloride. Stimulation of b3-AR signiﬁcantly
reduced urine excretion of water and the same electrolytes.
Moreover, BRL37344 promoted a potent antidiuretic effect
in AVPR2-null mice. Thus, our ﬁndings are of potential
physiologic importance as they uncover the antidiuretic
effect of b3-AR stimulation in the kidney. Hence, b3-AR
agonism might be useful to bypass AVPR2-inactivating
mutations.
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Kidney International (2016) 90, 555–567I n the kidney, the antidiuretic hormone arginine vaso-pressin (AVP) is a critical regulator of water and electrolytehomeostasis. AVP is released from the pituitary gland into
the bloodstream and binds to the type 2 vasopressin receptor
(AVPR2),1 a G protein–coupled receptor localized in the thick
ascending limb of Henle, the distal convolute tubule, and the
collecting duct, acting mainly through the cAMP–protein
kinase A pathway.
In the thick ascending limb of Henle, AVP stimulates NaCl
reabsorption across the Na-K-Cl cotransporter (NKCC2),
increasing its phosphorylation,2 thus generating the cortico-
medullary osmotic gradient providing the driving force for
water reabsorption in the kidney tubules.
In the CD, AVP stimulates the exocytosis of the water
channel aquaporin 2 (AQP2)3 at the apical membrane of the
principal cells, dramatically increasing water reabsorption
(for a review, see ref. 4). Inactivating mutations of the AVPR2
gene cause X-linked nephrogenic diabetes insipidus (XNDI),
characterized by constant diuresis and the risk of severe
dehydration.5 Many studies have shown that hormones other
than AVP also exhibit antidiuretic effect,6–10 suggesting novel
strategies to manage XNDI.
The b-adrenergic system controls several renal functions.
In particular, types 1 and 2 b-adrenoreceptors (b1-2-AR)
11
regulate renal blood ﬂow, glomerular ﬁltration rate (GFR),
sodium and water reabsorption, acid-base balance, and
secretion of renin (for a review, see Johns et al.12).
Among b-ARs, the b3-AR is the last identiﬁed member of
this family. At ﬁrst, it was shown to regulate lipolysis and
thermogenesis in adipose tissue,13 whereas subsequently it
was shown to play important roles in the pathophysiology of
the cardiovascular14 and urinary15 systems. However, its
expression and possible physiologic role in the kidney
remains to be fully clariﬁed. There are indications in mice that
b3-AR mRNA is expressed by renal arteries.
16 In addition, in
the rat kidney, a cDNA microarray screening showed that
b3-AR is expressed in the kidney medulla.
17 Moreover, in
humans, b3-AR polymorphisms seem to be associated with
the effect of thiazide diuretics,16,18 suggesting a role for b3-AR
in regulating renal water reabsorption. In this respect,
demonstrating this novel role of b3-AR in renal physiology is
particularly intriguing in light of potential therapeutic ap-
plications of b3-AR–acting drugs in diseases characterized by555
bas i c re sea r ch G Procino et al.: b3-AR stimulation triggers antidiuresis in the kidneyaltered diuresis. Moreover, b3-AR is relatively resistant to
agonist-induced desensitization,19 which would ensure pro-
longed pharmacologic stimulation in vivo. In addition, due to
the limited number of tissues expressing b3-AR, compared
with b1-2-AR, b3-AR agonists are supposed to show a low
systemic off-target effect.14RESULTS
b3-AR expression in the mouse kidney
Reverse transcriptase polymerase chain reaction revealed that
b3-AR mRNAwas clearly detectable in the RNA samples from
the mouse kidney, brown adipose tissue, and bladder
(Figure 1a). In particular, the intron-spanning primers
ampliﬁed 2 bands of 234 bp and 337 bp, representing b3a-AR
and b3b-AR transcripts, respectively.
20 Sequencing conﬁrmed
the speciﬁcity of the obtained bands (data not shown).Figure 1 | Expression of b3-ARs mRNA and protein in mouse
kidney. (a) Total RNA from mouse kidney was probed for the
presence of mRNA coding b3-adrenergic receptors (b3-ARs). Brown
adipose tissue and bladder were used as positive controls. Two
amplicons corresponding to b3b-AR (337 bp) and b3a-AR (234 bp)
were visualized in all samples. Control reverse transcriptase
polymerase chain reaction was performed using primers amplifying
mouse b-actin. (b) Total protein extracts from mouse kidney
cortex and total medulla were analyzed by Western blotting using
anti–b3-AR antibodies. Two bands, corresponding to the core and the
glycosylated protein, were detected in the kidney fractions at the
same molecular size as those revealed in brown adipose and urinary
bladder. Experiments were repeated 3 times with comparable results.
RT-PCR, reverse transcriptase polymerase chain reaction.
556Immunoblotting analysis revealed that mouse kidney
cortex and total medulla expressed a band of 44 kDa for the
core protein and 1 at 68 kDa for the glycosylated form in
all samples (Figure 1b). Both bands were also revealed in
b3-AR–expressing control tissues.
Immunolocalization of b3-ARs in the mouse kidney
As shown in Figure 2, b3-AR was expressed at the apical and
basolateral membrane of the epithelial cells of the thin
ascending limb, identiﬁed by the presence of the kidney-
speciﬁc chloride channel ClC-K1.21,22 b3-AR was also local-
ized at the basolateral membrane of the epithelial cells of (i) the
thick ascending limb of Henle, expressing the apical NKCC2
cotransporter23; (ii) the distal convolute tubule, expressing the
apical thiazide-sensitive NaCl symporter (NCC)24; and (iii) the
cortical CD and the outer medullary CD (the latter not
shown), expressing AQP2 at the apical membrane.25 The
staining for b3-AR completely disappeared when the anti–b3-
AR antibody used for immunoﬂuorescence was preadsorbed
on its immunizing peptide (Supplementary Figure S1).
We also demonstrated that b3-AR was neither expressed in
the proximal convolute tubule nor in the thin descending
limb of Henle’s loop, the inner medullary CD, and the vasa
recta (Supplementary Figure S2). Overall, the current data
show that b3-AR is localized in those nephron tracts also
expressing AVPR2.
Effect of b3-AR activation on cAMP production, AQP2 traf-
ﬁcking, and NKCC2 phosphorylation: ex vivo experiments
Our ﬁnding that b3-AR is expressed in the AVPR2-positive
kidney segments prompted us to investigate whether b3-AR
activation may mimic the effect of AVP on cAMP production,
AQP2 intracellular trafﬁcking, and NKCC2 activation. Using
an ex vivo model consisting of freshly isolated mouse kidney
tubule suspensions, we measured changes in intracellular
cAMP concentrations in response to either the speciﬁc b3-AR
agonist BRL37344 (1, 10, 100 mM) or the AVP analog 1-
deamino-8-D-arginine-vasopressin (dDAVP), 107 M, used
as positive control for cAMP production (Figure 3a). Results
are reported as the percentage of the cAMP concentration
measured in resting tubules. Treatment with BRL37344 led to
a concentration-dependent increase in intracellular cAMP
levels, with the maximal effect observed at 10 mM (þ173%,
P < 0.0001).
Accordingly, we used 10 mM BRL37344 for all the
following experiments performed in freshly isolated livemouse
kidney slices, untreated (resting) or incubated with either
dDAVP or BRL37344 (Figure 3b). Confocal microscopy
showed that both BRL37344 and dDAVP promoted AQP2
accumulation at the luminal plasma membrane of cortical
collecting duct cells (Figure 3b, white arrows) compared with
the cytoplasmic localization of AQP2 observed in control slices
(Figure 3b, white arrowheads). In line with the absence of
b3-AR in the inner medullary CD, BRL37344 failed to induce
AQP2 apical accumulation in this portion of the CD (not
shown). Importantly, the effect of BRL37344 was prevented byKidney International (2016) 90, 555–567
Figure 2 | Immunolocalization of b3-AR in mouse kidney. Parafﬁn-embedded kidney sections (C57BL6/J, wild type) were immunostained
with anti–b3-adrenergic receptor (b3-AR) antibodies (green) and costained with antibodies against speciﬁc markers of different segments of the
kidney tubule: kidney-speciﬁc chloride channel (CLC-K) channel for the thin ascending limb (tAL), Na-K-Cl cotransporter (NKCC2) for the
thick ascending limb (TAL), NaCl symporter (NCC) for the distal convolute tubule (DCT), and aquaporin 2 (AQP2) for the cortical collecting duct
(CCD) (all in red). Overlay of the each double-staining experiment indicated signiﬁcant expression of b3-AR in the tAL, TAL, DCT, and CCD.
Drawings of the nephron on the right show in light green the b3-AR–positive segments. The same results were obtained in 5 different animals
(bar ¼ 20 mm).
G Procino et al.: b3-AR stimulation triggers antidiuresis in the kidney bas i c re sea r chpreincubation with either the b3-AR-selective antagonist
L748,33726 or the protein kinase A inhibitor H89.27
Next, we evaluated the level of NKCC2 phosphorylation
under the same experimental conditions using an antibodyKidney International (2016) 90, 555–567against the regulatory phosphothreonine residues in the
N-terminus of NKCC2.28 Western blotting (Figure 3c and d)
showed that p-NKCC2 increased by about 5-fold after
BRL37344 treatment compared with resting conditions, an557
Figure 3 | Ex vivo b3-AR activation in a kidney tubule: intracellular cAMP measurements, AQP2 subcellular localization, and NKCC2
phosphorylation. (a) 1-Deamino-8-D-arginine-vasopressin (dDAVP)– and BRL37344 (BRL)-induced cAMP production in mouse kidney tubule
suspensions. Freshly isolated tubule suspensions from wild-type mice (12-week-old males, 3 per individual experiment) were pooled and
equally distributed into 24-well plates. Samples were treated with dDAVP (107 M) or with the indicated concentrations of BRL for 60 minutes at
37 C. Total cAMP-generated in each well was normalized to the protein content. Three independent experiments were carried out. Data are
expressed as the percentage of the cAMP content measured in resting cells  SEM. Signiﬁcant differences between means were tested by
1-way analysis of variance with the Newman-Keuls posttest. Signiﬁcance was accepted for P values < 0.05. ***P< 0.0001, **P < 0.001 compared
with resting tubules. ##P < 0.001 compared with 1 mM BRL. (b) Freshly isolated kidney slices (250 mm) were rapidly cut after sacriﬁce,
maintained in CO2-equilibrated culture medium at 37 C, left untreated (resting), or incubated with dDAVP (10
7 M) or with BRL (10 mM BRL).
BRL was also incubated after preincubation with either the b3-AR–antagonist (L748,337, 10
7 M) or the protein kinase A inhibitor (H89) (105 M).
Slices were treated as described and ﬁxed, and ultrathin sections were stained for aquaporin 2 (AQP2) and b3-adrenergic receptor (b3-AR) and
subjected to confocal microscopy. BRL was as effective as dDAVP in promoting AQP2 expression at the apical plasma membrane of cortical and
outer medullary collecting duct cells (white arrows) compared with the intracellular localization of AQP2 observed in untreated samples
(resting) or samples incubated with BRL after preincubation with L748,337 or H89 (white arrowheads) (bar ¼ 15 mm). (c) Kidney slices were
treated as described, then lysed, and total protein extracts underwent Western blotting analysis using the anti–phosphorylated Na-K-Cl
cotransporter (pNKCC2) and the anti–total NKCC2 antibodies. (d) Densitometric analysis showed a ﬁve-fold increase in pNKCC2 (normalized
to total NKCC2) in samples treated with BRL or dDAVP, and the effect of BRL was signiﬁcantly prevented by L748,337 and H89. Data are
provided as mean  SEM and expressed as a percentage of the resting condition. Signiﬁcant differences between means were tested by 1-way
analysis of variance with the Newman-Keuls posttest. ***P < 0.001. Comparable results were obtained in 3 different mice. NKCC2, Na-K-Cl
cotransporter; NS, not signiﬁcant.
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G Procino et al.: b3-AR stimulation triggers antidiuresis in the kidney bas i c re sea r cheffect comparable to that obtained with dDAVP. Pretreatment
with either L748,337 or H89 signiﬁcantly prevented this effect
of BRL37344. Of note, incubation of kidney slices with either
L748,337 or H89 alone did not change AQP2 subcellular
localization or NKCC2 phosphorylation compared with
resting slices (not shown).
To conﬁrm that these effects of BRL37344 were ascribable
to b3-AR stimulation, we repeated these experiments on live
kidney slices from b3-AR–null mice (b3-AR
/).29 Impor-
tantly, in the absence of b3-AR functional expression,
BRL37344 promoted neither AQP2 apical accumulationFigure 4 | BRL37344 failed to induce AQP2 apical expression and NK
isolated kidney slices (250 mm) were obtained from b3
/AR (b3-adrener
37 C, and left untreated (resting) or incubated with desmopressin (dDA
sections (5 mm) were stained for AQP2 (aquaporin 2) and subjected to co
promote AQP2 expression at the apical plasma membrane of cortical and
control to promote AQP2 apical expression (bar ¼ 10 mm). Arrows indicat
staining. (b) Slices were also lysed and protein extracts subjected to We
(pNKCC2) and total Na-K-Cl cotransporter (NKCC2) antibodies. (c) Densito
b3
/AR mice, BRL was unable to increase NKCC2 phosphorylation comp
the percentage of the resting condition. Signiﬁcant differences between
Keuls posttest. ***P < 0.0001. Comparable results were obtained in 3 di
Kidney International (2016) 90, 555–567(Figure 4a) nor NKCC2 phosphorylation (Figure 4b and c). In
addition, in b3-AR
/ mice, 10 mM BRL37344 was unable to
promote intracellular cAMP elevation in isolated kidney tu-
bules (not shown).
Effect of b3-AR knockout on water and electrolyte handling in
the mouse kidney
The effect of b3-AR agonism on AQP2 and NKCC2, the major
players involved in antidiuresis, prompted us to investigate
whether b3-AR inactivation may affect water and electrolyte
handling in the kidney in vivo. To this end, we evaluated theseCC2 phosphorylation in the kidney of b3-AR–null mice. (a) Freshly
gic receptor) mice, maintained in CO2-equilibrated culture medium at
VP, 107 M) or BRL37344 (BRL, 10 mM). Slices were ﬁxed, and ultrathin
nfocal laser-scanning microscopy. In b3
/AR mice, BRL was unable to
outer medullary collecting duct cells. dDAVP was used as an internal
e apical plasma membrane staining. Arrowheads indicate intracellular
stern blotting analysis with antiphosphorylated Na-K-Cl cotransporter
metric analysis of pNKCC2, normalized to total NKCC2, showed that in
ared with dDAVP. Data are provided as mean  SEM and expressed as
means were tested by 1-way analysis of variance with the Newman-
fferent mice.
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Figure 5 | Mice lacking functional expression of b3-AR showed mild polyuria and reduced urine osmolality. (a) b3-adrenergic receptor–
null mice (b3-AR
/) and their age-matched controls (b3-AR
þ/þ) (8 in each group) were individually housed in metabolic cages for 5 days, and
24-hour urine output, urine osmolality, and water intake were measured daily. The analysis reports the mean  SEM values relative to 24-hour
urine collection. In b3-AR
/ mice, urine output was nearly 77% higher, urine osmolality 30% was lower, and water intake was 41% higher
compared with control b3-AR
þ/þ mice. Statistical analysis was performed by unpaired t-test. *P < 0.05. (b) The same experimental protocol
was applied to b1-2-AR-null mice (b1-2-AR
/) and their age-matched controls (b1-2-AR
þ/þ) (8 in each group). No statistically signiﬁcant dif-
ference was observed in urine parameters and water intake between the 2 experimental groups. (c) Immunoﬂuorescence analysis showed that
b3-AR
/ mice have reduced plasma membrane expression and higher subapical localization of AQP2 compared with control b3-AR
þ/þ mice
(bar ¼ 10 mm). (d) Immunoﬂuorescence analysis with the antiphosphorylated Na-K-Cl cotransporter (pNKCC2) showed also that b3-AR/ mice
have reduced levels of activated NKCC2 (pNKCC2) (bar ¼ 30 mm). Comparable results were obtained in 3 different mice.
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/ mice29 lacking b3-AR functional
expression and b1-2-AR
/ knockout mice,30 in which b3-AR is
the only expressed b-AR. Age-matched wild-type (wt) mice of




/, diuresis was higher (by 77%), urine
osmolality was lower (by 30%), and water intake was increased
(by 40%) compared with b3-AR
þ/þ (Figure 5a). In contrast,
urine parameters and water intake were comparable between
b1-2-AR
þ/þ and b1-2-AR
/ mice (Figure 5b). No signiﬁcant
differences in food intake were observed between mouse strains
(not shown).
In line with these results, immunoﬂuorescence
analysis showed that, compared with control b3-AR
þ/þ mice,
b3-AR
/ mice have reduced AQP2 plasma membrane
expression and increased subapical localization (Figure 5c).
Analysis of urine electrolytes, reported in Table 1, showed
that b3-AR
/ mice have signiﬁcantly higher urine excretion
of Naþ, Kþ, and Cl compared with their age-matched
b3-AR
þ/þ. Instead, the plasma concentration of the same
electrolytes and the GFR were comparable between b3-AR
/
and b3-AR
þ/þ mice. These results suggest reduced activity of
the NKCC2 transporter in b3-AR
/ mice.
Immunoﬂuorescence analysis showed that in b3-AR
/
mice, the antibody against phosphorylated NKCC2 detected a
lower amount of activated NKCC2 in the outer medulla
compared with b3-AR
þ/þ mice (Figure 5d).
To further support this evidence, we analyzed the effects of
bumetanide injection on natriuresis in both b3-AR
/ and b3-
ARþ/þ mice (Supplementary Figure 3c and d). Natriuresis was
higher in b3-AR
þ/þ than in b3-AR
/ mice (355.4  21.55%
vs. 287  27.5%; P < 0.0001), conﬁrming that b3-AR/ mice
have less basal NKCC2 cotransporter activity to inhibit.
Of note, the maximal urine concentrating ability of
b3-AR
/ mice on a water deprivation test was comparable to
that of b3-AR
þ/þ mice (Supplementary Figure S3a and b).
Effect of b3-AR stimulation on urine output
Next, to uncover the possible antidiuretic effect of pharma-
cologic stimulation of b3-AR in mice, we examined whetherTable 1 | Plasma electrolyte concentrations, renal 24-h








Naþ (mEq/l) 139.0  5.57 141.3  0.67 NS
Kþ (mEq/l) 6.73  0.29 6.43  0.19 NS
ClL (mEq/l) 108.0  3.22 106.3  2.67 NS
Ca2þ (mEq/l) 3.16  0.53 3.34  0.44 NS
Urine
Naþ (mEq/24 hr) 019  0.02 0.27  0.01 P < 0.01
Kþ (mEq/24 hr) 0.18  0.02 0.23  0.01 P < 0.05
ClL (mEq/24 hr) 0.45  0.04 0.59  0.03 P < 0.01
Ca2þ (mEq/24 hr) 0.005  0.0006 0.005  0.0005 NS
GFR (ml/min) 235.5  20.76 253.8  30.94 NS
Food intake (g) 5.07  0.08 5.14  0.08 NS
Values are means  SEM of measurements in 8 mice/genotype. Statistical analysis
was performed using an unpaired t test.
GFR, glomerular ﬁltration rate; NS, not signiﬁcant.
Kidney International (2016) 90, 555–567BRL37344 could per se induce antidiuresis. b3-AR
þ/þ and
b3-AR
/ mice received a single i.p. injection of BRL37344
(0.6 mg/kg) or phosphate-buffered saline (PBS) alone
(vehicle). Urine samples were collected for 4 hours after in-
jections, the ﬁrst time point at which all BRL37344-treated
animals began to urinate. Diuresis, urine osmolality, and
urine electrolyte excretion were analyzed and are shown in
Figure 6. Notwithstanding the differing diuresis in b3-AR
/
and b3-AR
þ/þ mice, we expressed our results as a percentage
of the values measured in vehicle-treated animals of each
genotype. Strikingly, BRL37344 greatly reduced the diuresis in
b3-AR
þ/þ mice but not in b3-AR
/ mice (Figure 6a).
Concomitantly, BRL37344 signiﬁcantly increased urine
osmolality only in b3-AR
þ/þ mice (Figure 6b). Interestingly,
in b3-AR
þ/þ mice, urine excretion of Naþ, Kþ, and Cl,
normalized to the volume of diuresis, were signiﬁcantly
reduced by BRL37344 (Figure 6c–e). Of note, the GFR in
b3-AR
þ/þ mice, measured at 1, 2, 3, and 4 hours after
BRL37344 treatment, was not affected (Figure 6f).
Effect of b3-AR stimulation on diuresis of mice lacking AVPR2
Next, we investigated whether the potent antidiuretic effect of
BRL37344 observed in b3-AR
þ/þ mice could bypass the inac-
tivation of the AVP signaling in mice lacking AVPR2.12,31 Mice
received a single i.p. injection of BRL37344 (0.6 mg/kg) or PBS
alone (vehicle). Urine samples were collected every hour for 3
hours, and diuresis (Figure 7a) and urine osmolality
(Figure 7b) were reported. Strikingly, 1 hour after the injection,
the urine output of all BRL37344-treated mice was reduced to
zero compared with vehicle-treated mice (Figure 7a, 1 hour).
Therefore, we could not measure urine osmolality at this time
point (Figure 7b, 1 hour). Two hours after injection, the
diuresis of BRL37344-treated mice was still dramatically
reduced compared with vehicle-treated animals (Figure 7a,
2 hours) and urine osmolality increased (Figure 7b, 2 hours).
Three hours postinjection, the effect BRL37344 on diuresis still
persisted (Figure 7a, 3 hours), whereas that on urine osmolality
partially reversed (Figure 7b, 3 hours).
DISCUSSION
The possible expression and physiologic role of b3-AR in the
kidney has not been investigated in depth thus far. The
present results show b3-AR expression in the same AVPR2-
expressing tubules. Because it is known that, similar to
AVPR2, b3-AR activates the cAMP pathway,
32 we hypothe-
sized that pharmacologic stimulation of b3-AR might regulate
the trafﬁcking/activity of AQP2 and NKCC2 involved in the
AVP-elicited antidiuresis in the kidney.2,3 We ﬁrst demon-
strated that BRL37344 signiﬁcantly increases cAMP produc-
tion and promotes both AQP2 apical accumulation and
NKCC2 phosphorylation/activation, suggesting that, similar
to AVP, b3-AR agonists may increase reabsorption of water
and solutes in the kidney.
The pharmacologic proﬁle of BRL37344 indicates that it
may have an intrinsic activity at b1-ARs or b2-ARs.
33 As
shown by the current results, BRL37344 effects on AQP2 and561
Figure 6 | Effect of b3-AR stimulation on urine concentrating ability in b3-AR
D/Dmice. b3-adrenergic receptor (b3-AR)–null (b3-AR
/) mice
and their age-matched controls (b3-AR
þ/þ) (10 of each genotype) were individually acclimatized in metabolic cages for 48 hours; 5 received
a single i.p. injection of BRL37344 (BRL) (0.6 mg/kg), whereas 5 control animals received phosphate-buffered saline alone (vehicle). Urine
samples were collected for 4 hours after injection. Urine output (a) and urine osmolality (b) were measured in b3-AR
þ/þ and b3-AR
/ mice and
expressed as a percentage of control values measured in vehicle-injected animals  SEM. Urine output of b3-ARþ/þ mice decreased w70%
and urine osmolality increased w40% after BRL37344 (BRL) injection. No signiﬁcant effect was seen in b3-AR
/ mice. Signiﬁcant differences
between means were tested by 1-way analysis of variance with the Newman-Keuls posttest. *P < 0.05, ***P < 0.0001. (c,d,e) Urine excretion of
Naþ, Kþ, and Cl–, normalized for the urine volume, measured in b3-AR
þ/þ mice. Data are reported as a percentage of the values measured
in vehicle-injected mice  SEM. Signiﬁcant differences between means were tested by the Mann-Whitney U test. *P < 0.05. (f) Glomerular
ﬁltration rate (GFR) of b3-AR
þ/þ conscious mice was measured at 1, 2, 3, and 4 hours after injection of BRL or vehicle alone. No signiﬁcant
difference was found at each time point between BRL- and vehicle-injected mice. Signiﬁcant differences between means were tested by 2-way
analysis of variance with a Bonferroni posttest.
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Figure 7 | b3-Adrenergic receptor stimulation promotes
antidiuresis in mice lacking functional expression of the arginine
vasopressin receptor type 2. Ten V2Rﬂ/yEsr1-Cre mice were
acclimatized inmousemetabolic cages for 48 hours; 5 received a single
i.p. injection of BRL37344 (0.6 mg/kg), whereas 5 control mice received
phosphate-buffered saline alone (vehicle). Urine samples were
collected every hour for 3 hours from both groups, and urine output (a)
and urine osmolality (b) at each time point were reported. One hour
after the injection, the urine output of BRL37344-treated mice was
reduced to zero compared with vehicle-injected animals (vehicle)
(diuresis, 1 hour). Twohours after injection, urine output of treatedmice
was still dramatically reduced compared with control animals (diuresis,
2 hours). Urine osmolality increased in BRL37344-injected animals
(urine osmolality, 2 hours). At 3 hours postinjection, the effect of BRL on
the urine output still persisted (urine output, 3 hours), whereas the
effect on urine osmolality partially reversed (urine osmolality, 3 hours).
The analysis reports the mean  SEM values. Signiﬁcant differences
betweenmeasurements were tested by 2-way analysis of variance with
a Bonferroni posttest for diuresis and by 1-way analysis of variance with
a Bonferroni posttest. *P < 0.05; ***P < 0.001.
G Procino et al.: b3-AR stimulation triggers antidiuresis in the kidney bas i c re sea r chNKCC2 are prevented by the b3-AR antagonist L748,337 and
are not observed in b3-AR
/ mice, thus supporting the
notion that BRL37344 acts selectively at b3-AR at the dose
used and excluding an off-target effect.
Here we also show that b3-AR
/ mice are characterized
by mild polyuria, lower urine osmolality, and increased uri-
nary excretion of Naþ, Kþ, and Cl but not Caþþ. Increased
water excretion is in line with the observed reduced plasma
membrane expression of AQP2 in the cortical collecting duct
of b3-AR
/. In addition, increased Naþ, Kþ, and Cl
excretion in b3-AR
/ is in line with decreased NKCC2
activity, as also supported by the ﬁndings that b3-AR
/ mice
show less activated NKCC2 at the plasma membrane and a
less pronounced natriuretic response to bumetanide.Kidney International (2016) 90, 555–567The fact that food consumption in b3-AR
/ mice is
comparable to that of b3-AR
þ/þ mice (Table 1) seems to
exclude that solute diuresis can explain the polyuria of
b3-AR
/ mice. Neither defect of AVP release (central poly-
dipsia) can explain the polyuria of b3-AR
/ mice because
these mice show normal urine-concentrating abilities under a
water deprivation challenge.
We also show that b3-AR
/mice have normal plasma levels
of Naþ, Kþ, Cl, and Caþþ indicating that their polyuric
phenotype is neither induced by hypercalciuria/
hypercalcemia nor by hypokalemia.34–36 In addition, the
polyuria in b3-AR
/mice is not a consequence of an increased
GFR, which is comparable to that in b3-AR
þ/þ mice. On the
other hand, b1-2-AR
/ do not show alterations of urine output
and osmolality, suggesting that b3-AR, rather b1-AR and b2-
AR, regulate these urine parameters. However, the question
whether b3-AR is more important than b1-AR and b2-AR in
baseline renal function cannot be solved by the current study
as we cannot compare the urine-concentrating ability of b3-
AR/ and b1-2-AR
/ mice. The 2 strains result from a
different genetic background, and early studies showed that
renal parameters signiﬁcantly differ in mice of different
strains.37
In line with the stimulatory effect of b3-AR activation on
AQP2 subcellular localization and NKCC2 phosphorylation,
BRL37344 exerts a potent antidiuretic effect in b3-AR
þ/þ
mice but not in b3AR
/ mice, thus conﬁrming our ex vivo
data on its speciﬁc action at the b3-AR. The additional ﬁnding
that in b3-AR
þ/þ mice, BRL37344 reduces urinary excretion
of Naþ, Kþ, and Cl but not Caþþ and induces a 70%
reduction of the urine output, whereas urine osmolality is
increased by w40% may be explained by assuming that
b3-AR stimulation promotes not only water but also salt
reabsorption in the kidney. In line with this possibility, the
strong reduction of urine output observed in BRL37344-
treated mice is independent of the decrease in the GFR.
b3-ARs are also expressed in the hypothalamus
38; thus, the
possibility exists that the antidiuretic effect of BRL37344 may
involve hypothalamic regulation of AVP release. Our results in
AVPR2-null mice31 seem to exclude this possibility. In these
mice, the classic symptoms of XNDI develop.39–41 As shown
here, a single i.p. injection of BRL37344 greatly reduces the
diuresis and increases urine osmolality, supporting the notion
that, in vivo, b3-AR agonism triggers AVP-independent anti-
diuresis. In addition, results in live kidney slices, demon-
strating that BRL37344 induces cAMP production, AQP2
plasma membrane accumulation, and NKCC2 phosphoryla-
tion/activation in the thick ascending limb of Henle, provide
additional, although indirect, evidence that BRL37344 triggers
its effect independently of central b3-AR activation.
The current results cannot exclude that the effects of
BRL37344 on urine output may be related to the systemic
effects of the drug on arterial pressure. However, it has been
shown in rats that BRL37344 reduces arterial pressure by
w14%42; therefore, it is unlikely that such an effect may be
responsible for the observed 70% reduction in urine output.563
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mice, b3-ARs are expressed in most of the AVP-sensitive
nephron segments; (ii) b3-AR stimulation promotes AQP2
plasma membrane accumulation and NKCC2 activation, thus
increasing water and salt reabsorption in the kidney tubule;
(iii) this effect is likely mediated by an increase of intracellular
cAMP; and (iv) b3-AR agonism induces antidiuresis in mice
lacking AVPR2.
Taken together, these data suggest an unexplored role of
sympathetic stimulation via the b3-AR in promoting
antidiuresis under physiologic conditions. Some evidence
indicates that there is a synaptic contact between renal
sympathetic varicosities and renal tubular epithelial cell
basolateral membranes.12,43 In this respect, the current data
support the hypothesis that sympathetic stimulation of
b3-ARs, upregulating NKCC2 and AQP2 activity, can enhance
solutes and water reabsorption in the nephron, thus eliciting
an antidiuretic effect. Although we restricted our investigation
to the regulatory role of b3-ARs on AQP2 and NKCC2, the
possible effect of b3-AR stimulation on other Na/Cl trans-
porters or additional AQPs, participating in the countercur-
rent multiplier system, is worth further investigation.
The observation that b3-AR
/mice are polyuric but show
normal urine-concentrating ability during water deprivation
suggest that, under physiologic conditions, b3-AR activation
by sympathetic nerves does not provide an additional
mechanism, corroborating the kidney antidiuretic response to
AVP. Although much work remains to be done to fully un-
derstand the role of b3-ARs in water and salt reabsorption
during sympathetic activation, the current results are poten-
tially relevant for the development of novel pharmacologic
approaches to the treatment of diseases caused by AVPR2-
altered signaling, including XNDI, polycystic kidney dis-
eases, and the syndrome of inappropriate secretion of AVP.
For instance, in XNDI patients, b3-AR agonists may bypass
the lack of AVPR2 function, restore NKCC2 and AQP2
activity, and improve the unpaired urine concentration
mechanism. It must be emphasized that patients with auto-
somal forms of NDI40 due to mutations of the AQP2 gene
would not beneﬁt from this potential treatment.
Further studies are needed to verify this proof-of-concept,
but the ameliorative effect of BRL37344 on renal concen-
trating abilities of AVPR2-null mice strongly encourages
studies in this direction. In particular, we suggest that agonists
of the human b3-AR, such as mirabegron,
44 already used to
treat an overactive bladder, may either improve the impaired
concentrating ability of the kidney or increase the beneﬁcial
effects of the current XNDI therapy.MATERIALS AND METHODS
Antibodies and reagents
Polyclonal antibodies against b3-AR (cat. nos. sc-50436 and sc-1473)
were obtained from Santa Cruz Biotechnology (Dallas, TX) and were
previously validated for Western blotting and immunoﬂuorescence
analysis.45,46 Antibodies against AQP1 (cat. no. sc-20810), and CD-31
(cat. no. sc-1506), BRL37344 (cat. no. sc-200154), L748,337 (cat. no.564sc-204044) were from Santa Cruz Biotechnology. H-89 (cat. no.
B1427), and [deamino-Cys1, D-Arg8]-vasopressin (dDAVP, cat.
no. V-1005) were from Sigma (St. Louis, MO). Antibody anti-CLC-K
(cat. no. ACL-004) was from Alomone Labs (Jerusalem, Israel). An-
tibodies anti-NKCC2 (cat. no. AB3562P) were from Merck Millipore
(Billerica, MA). Antibodies anti-NCC (cat. no. SPC-402D) were from
StressMarq Biosciences Inc. (Victoria, BC, Canada). The antibody
against human AQP2 was previously described.47 The antibody against
the phosphorylated threonines 96 and 101 of phosphorylated mouse
NKCC228 was kindly provided by Prof. Biff Forbush, Yale University.
b3-AR pharmacology
BRL37344 is a well-known b3-AR agonist
48 that has been previously
used in mice.49–51 BRL37344 displays a rank order of potency at the
human b-ARs, that is, b3-AR > b2-AR > b1-AR, with an approxi-
mately 20-fold and 100-fold higher selectivity for b3-AR versus
b2-AR and b1-AR, respectively.
52 BRL37344 has been found to be
effective at 10 mM in the human isolated internal anal sphincter
model,53 in human retinal endothelial cells,54 and in mouse retinal
explants.55
L748,337 has been reported as one of the very few antagonists
with a high selectivity for b3-AR.
56 Nonetheless, L748,337 remains
the most suitable b3-AR antagonist currently available.
26
RNA isolation and reverse transcriptase polymerase chain
reaction
Total RNA was extracted from mouse brown adipose tissue, the
bladder, and the kidney by the TRIzol reagent and reverse-
transcribed into cDNA using SuperScript VILO cDNA Synthesis
Kit (Thermo Fisher Scientiﬁc, Waltham, MA).
The mouse b3-AR intron-spanning primers were previously re-
ported.20 As a positive control, mouse b-actin cDNA was ampliﬁed
using speciﬁc primers. Polymerase chain reaction was performed
using Taq DNA polymerase recombinant (Life Technologies, Carls-
bad, CA) according to the following: (94C, 3 minutes)  1 cycle
and (94C, 45 seconds; 55C, 30 seconds; 72C, 1 minute)  40
cycles. Ampliﬁed products were analyzed on 3% agarose gel.
Sequencing was performed by BMR Genomics (Padova, Italy), using
the method of Sanger.
Cell and tissue fractionation and immunoblotting
Brown adipose tissue, bladder, and kidney cortex/total medulla were
isolated from male C57BL/6J mice and homogenized in radio-
immunoprecipitation assay buffer.57 Where reported, kidney slices
were lysed in antiphosphatase buffer.2
Fifteen micrograms of each lysate were separated by sodium
dodecylsulfate-polyacrylamide gel electrophoresis and analyzed by
Western blotting. After blocking with 3% bovine serum albumin,
blots were incubated with anti–b3-AR antibody (sc-50436, 1:200)
and anti–p-NKCC2 antibodies (1:1000) followed by horseradish
peroxidase–conjugated secondary antibody.
Blots were revealed by enhanced chemiluminescence, with
Chemidoc XRS, equipped with Image Lab Software (Bio-Rad, Her-
cules, CA) and quantiﬁed with ImageJ software.
Immunoﬂuorescence
Mouse kidneys were ﬁxed with 4% paraformaldehyde in PBS at 4C,
dehydrated in graded ethanol, and embedded in parafﬁn wax. Serial
sections, 5 mm thick, were deparafﬁnized, rehydrated, and subjected
to immunoﬂuorescence analysis. Antigen retrieval was performed by
boiling sections in citrate buffer (10 mM sodium citrate, pH 6). AfterKidney International (2016) 90, 555–567
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sections were incubated with the primary antibodies b3-AR (sc-
1473), AQP2, AQP1, CLC-K, NKCC2, CD31, NCC, and phosphor-
ylated NKCC2.
Sections were incubated with AlexaFluor-conjugated secondary
antibodies (Life Technologies). Confocal images were obtained with
a confocal microscope (TSC-SP2, Leica; Wetzlar, Germany).
Preparation of kidney tubule suspensions and cAMP assay
Kidneys from FVB/C57/129/DBA mice (10-week old males) were
minced and enzymatically digested as previously reported.10 Aliquots
of tubule suspensions were preincubated with the phosphodiesterase
inhibitor IBMX for 10 minutes at 37C. Subsequently, BRL37344 (1,
10, and 100 mM) or dDAVP (100 nM) were added, and reactions
were carried out for 45 minutes at 37C. Total intracellular cAMP
was determined by enzyme-linked immunosorbent assay, as previ-
ously reported.10
Kidney tissue slices: preparation and treatment
C57BL/6J male mice were anesthetized with tribromoethanol (250 mg/
kg) and killed by cervical dislocation. Kidneys were excised, and thin
transversal slices (250 mm) were cut using a McIlwain Tissue Chopper
(Ted Pella Inc.; Redding, CA, United States). Slices were left at 37C for
15 minutes in Dulbecco’s Modiﬁed Eagle Medium/F12 medium pre-
equilibrated with 5% CO2, then stimulated for 40 minutes with
dDAVP (107 M) or BRL37344 (105 M), the latter alone or after
30 minutes of preincubation with either L748,337 (107 M) or H89
(105 M). Slices were either processed for immunoblotting analysis or
ﬁxed in 4% paraformaldehyde and processed for immunoﬂuorescence
as described previously.
Animal studies
All animal experiments were approved by the Institutional Com-
mittee on Research Animal Care, in accordance with the Italian
Institute of Health Guide for the Care and Use of Laboratory Ani-
mals. Mice were maintained on a 12-hour light/12-hour dark cycle,
with free access to water and food.
b3-AR
/ and b3-AR
þ/þ mice58 were purchased from Jackson
Laboratory (Bar Harbor, ME, United States). b1-2-AR
/ and b1-2-AR
þ/þ
mice30 were generated as previously described.59,60 Metabolic cages
were used to measure urine output, osmolality, and water intake. Mice
received a single i.p. injection of BRL37344 (0.6 mg/kg) or PBS alone.
Electrolytes were measured using the ion selective electrode method.
The GFR of conscious mice was measured as previously
reported.61 AVPR2 knockout mice (V2Rﬂ/ﬂ and V2Rﬂ/y Esr1-Cre
mice) were previously described.31
V2Rﬂ/y Esr1-Cre mice received a single i.p. injection of BRL37344
(0.6 mg/kg) or PBS alone and urine output and osmolality were
monitored every hour for 3 hours. Urine osmolality was measured
using a vapor pressure osmometer.
Statistical analysis
For statistical analysis, GraphPad Prism software (La Jolla, CA) was
used. The statistical analysis performed is indicated in the ﬁgure legends.
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Figure S1. Pre-adsorption of anti b3-AR antibody on its immunizing
peptide completely abolished the immunostaining of b3-AR in mouse
kidney sections. Goat antib3-AR (#SC1473) was preadsorbed on its
immunizing peptide (SC1473p) and used to immunostained parafﬁn-
embedded mouse kidney sections. Compared to whole antibody,
immunodepleted antibody failed to detect b3-AR-positive tubule in
both kidney cortex and medulla (bar ¼ 50 mm).
Figure S2. Immunolocalization of b3-AR in mouse kidney. Parafﬁn-
embedded kidney sections (C57BL6/J, wt) were immunostained with
anti b3-AR antibodies (green) and co-stained with antibodies against
speciﬁc markers of different segments of the kidney tubule or
vasculature: AQP1 for the proximal tubule (PT) and the thin
descending limb (TDL), AQP2 for the inner medullary collecting duct
(IMCD) and CD31 for the endothelium of Vasa Recta (all in red).
Overlay of the each double staining experiment indicated that b3-AR
was neither expressed in the PT nor in the TDL nor in the IMCD nor in
the Vasa Recta. Drawings of the nephron on the right column indi-
cated in red the b3-AR-negative tubule or vascular portions. b3-AR
was expressed at the basolateral plasma membrane in all the tubules
where it is expressed. Same results were obtained in at least 5 animals
(bar ¼ 20 mm).
Figure S3. Water deprivation test and bumetanide-induced diuresis
and natriuresis. b3-AR-null mice (b3-AR-/-) and their age-matched
controls (b3-ARþ/þ) (N ¼ 8 for each group), were individually housed
in metabolic cages for 24 hours, then 4 animals per group were
subjected to water deprivation for 24 hours, while 4 animals had free
access to water (basal). The 24-hour urine output (A) and urine
osmolality (B) of control animals were set as 100%. Urine output of
water-deprived animals was reduced of 32% in b3-ARþ/þ mice and
of 40% in b3-AR-/- mice. Urine osmolality of water-deprived animals
was increased of 27% in b3-ARþ/þmice and of 28% in b3-AR-/- mice.
Data are provided as mean  SEM. Signiﬁcant differences between
means were tested by one-way analysis of variance ANOVA with
Newman-Keuls’s post-test. **P < 0.001, *P <0.05 No signiﬁcant
interstrain differences were observed. Urine output (C) and natriuresis
(D) after the i.p. injection of vehicle or 40 mg/kg bumetanide for 4
hours in b3-ARþ/þ and b3-AR-/- mice. The 4-hour urine output and
urine Naþ excretion of control animals was set as 100% (n ¼ 5). Data
are provided as mean  SEM. Signiﬁcant differences between means
were tested by one-way analysis of variance ANOVA with Newman-
Keuls’s post-test. ***P < 0.0001 for intrastrain differences between
vehicle and bumetanide treatments; xP < 0.01 for interstrain differ-
ences in the effects of bumetanide. The bumetanide-induced natri-
uresis was signiﬁcantly attenuated in b3-AR-/- mice compared with
b3-ARþ/þ.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.REFERENCES
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